Aquestive Therapeutics, Inc.
AQST
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for theā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.70
Price-0.67%
-$0.02
1Y
Price
Market Cap
$463.601m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-86.2%
EBITDA Margin-120.6%
Net Profit Margin-100.6%
Free Cash Flow Margin-86.2%
EBITDA Margin-120.6%
Net Profit Margin-100.6%
Free Cash Flow MarginRevenue
$50.271m
-24.6%
1y CAGR-1.6%
3y CAGR-2.7%
5y CAGREarnings
-$68.911m
-56.3%
1y CAGR-143.9%
3y CAGR-102.2%
5y CAGREPS
-$0.61
-39.2%
1y CAGR-81.0%
3y CAGR-50.9%
5y CAGRBook Value
-$34.054m
$141.125m
Assets$175.179m
Liabilities$133.578m
DebtDebt to Assets
94.7%
-2.6x
Debt to EBITDAFree Cash Flow
-$44.317m
-41.8%
1y CAGR-129.6%
3y CAGR-81.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company